Asthma Biologics Market By Asthma Type (Severe Eosinophilic Asthma, Allergic Asthma, Non-Eosinophilic Asthma, Late-Onset Asthma, Others), By Drug Class (Anti-IgE, Anti-IL5, Anti-IL4/IL13, Anti-TSLP, Others), By Age Group (Pediatric Patients, Adults, Geriatric Patients), By Route of Administration (Subcutaneous (SC), Intravenous (IV)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Clinics, Online Pharmacies), and By End User (Hospitals, Specialty Clinics & Pulmonology Centers, Research & Academic Institutes, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

---

What trends will shape Asthma Biologics Market in the coming years?

The Asthma Biologics Market accounted for USD 7.84 Billion in 2024 and USD 8.81 Billion in 2025 is expected to reach USD 28.20 Billion by 2035, growing at a CAGR of around 12.34% between 2025 and 2035. The asthma biologics market is defined as the industry that deals with advanced biologic disease therapies for asthma, especially against selective molecules and pathways that are involved in the pathogenesis. The treatments (usually monoclonal antibodies or other biologics) are created to treat patients with severe asthma unresponsive to other conventional drugs such as inhalers or steroids. Their goal is to decrease the inflammation, eliminate asthma attacks, and enhance lung performance. Major market participants are such drugs as Dupixent, Xolair, and Fasenra. It has a growing market because of the rising cases of asthma, demand for targeted therapy, and technological progress in the development of biologic drugs.

What do industry experts say about the Asthma Biologics market trends?

“Biologics have transformed severe asthma management by targeting specific inflammatory pathways, reducing exacerbations, and improving quality of life for patients who were previously uncontrolled on standard therapies.”

• Dr. Mario Castro, MD, MPH (Chief of Pulmonary and Critical Care Medicine, University of Kansas Medical Center)

“The introduction of biologics marks a precision medicine era in asthma care, allowing treatment to be tailored to the patient’s underlying phenotype and biomarkers rather than a one-size-fits-all approach.”

• Dr. Sally Wenzel, MD (Director, Asthma and Airway Center, University of Pittsburgh)

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Asthma Biologics market?

What are the advancements in biologics for asthma treatment?

The use of biologics to treat asthma has advanced the treatment of severe asthma, especially in patients with certain asthma phenotypes like eosinophilic asthma. Monoclonal antibodies for biologics address important inflammatory pathways for asthma, like interleukin-5 (IL-5) and immunoglobulin E (IgE). Clinical studies in journals such as The Lancet Respiratory Medicine and JAMA show that mepolizumab, benralizumab, and omalizumab significantly reduce exacerbations and improve lung function.

The American Lung Association reports that asthma affects nearly 25 million Americans, a large number of whom would be ideal candidates for biologics due to poor asthma control and frequent exacerbations. In addition, the NIH corroborates the increase in the use of biologics, citing a 25-30% decrease in severe asthma hospitalizations when biologic therapies are used. These therapies increase treatment options, especially for patients who have failed to respond to standard inhalers or oral corticosteroids.

How do increasing asthma prevalence rates drive market growth?

The asthma biologics market has been fueled by the growing incidence of asthma. Worldwide, there are over 262 million cases of asthma, which is a widely known chronic illness, as reported by the World Health Organization (WHO). The need for advanced treatments has increased alongside the number of cases caused by pollution and other environmental factors. Asthma is an illness that affects one in every thirteen people in the United States, especially children and women, as reported by the Centers for Disease Control and Prevention (CDC). Monoclonal antibodies and other asthma biologics are becoming the treatment of choice for individuals diagnosed with moderate to severe asthma. The market continues to grow as these treatments provide more solutions and as the demand for and knowledge about personalized care keep increasing.

How do side effects and safety concerns affect adoption rates?

Asthma biologics have side effects and safety concerns that greatly influence their adoption rates. Although biologics have demonstrated a promising outcome in the reduction of asthma symptoms and prevention of exacerbations, their possible adverse side effects, including allergic manifestations, infections, autoimmune complications, etc., can make patients hesitant to accept them. A study that was published in the American Journal of Respiratory and Critical Care Medicine reported that up to 25 per cent of patients participating in clinical trials had some kind of side effects that affected their future decisions on long-term treatment.

According to the report of the U.S. National Institutes of Health (NIH), biologics are sometimes viewed as the second-line therapy because of their high cost, side effects, and the requirement of special administration methods (such as injections or infusions). They are of particular concern in children's populations, among which the safety profiles are more closely examined. In a 2020 Journal of Asthma study, the authors emphasised that biologic therapies have a low adherence rate of 10-15 per cent of potential patients with asthma, implying that side effects are a critical barrier to wider use of the therapies.

What potential does expanding global healthcare access offer biologics?

Asthma biologics stand to gain a lot as governments seek to improve the management of chronic illnesses. Severe asthma can be better treated with biologics, which can improve patients’ quality of life and lower hospitalisation rates. The need for biologics is growing, especially in developing countries, with asthma affecting an estimated 262 million people worldwide, as reported by the World Health Organisation. The U.S. CDC emphasises the burden of severe asthma exacerbations on healthcare costs, indicating that biologics could be a source of savings in the long term.

As other illnesses get addressed, healthcare systems seem to prioritise chronic disease management, where biologics will be important in improving asthma control and in reducing deaths from asthma that exceed 400,000 annually, as the WHO estimates. Furthermore, wider availability of biologics globally may promote innovation in asthma therapies, leading to better care. This development could also encourage more partnerships among healthcare providers, governments, and pharmaceutical firms to tackle the global challenges of asthma.

What role does technological innovation play in biologic treatments' future?

Innovations in technology are vital if we want to progress in biological treatments for asthma and increase their effectiveness and accessibility. Developments in medicines, like monoclonal antibodies, gene editing, and new drug delivery systems, create opportunities for treatments to be more accurate and patient-specific. As per the data from the NIH, biologic drugs such as omalizumab can decrease asthma attacks by 30%. Patient adherence and treatment results also improve with better delivery methods like enhanced inhalers and injectables.

The FDA has spoken about biologics, commending their specific impact and fewer side effects in contrast to conventional treatments. The incorporation of genomics and biomarkers also enables precision medicine, which complements the use of biologics and enables treatments to be designed and optimised for an individual. With such advanced innovations, asthma care stands to benefit enormously through more nuanced and effective strategies.

What are the key market segments in the Asthma Biologics industry?

Based on the Asthma Type, the Asthma Biologics Market has been classified into Severe Eosinophilic Asthma, Allergic Asthma, Non-Eosinophilic Asthma, Late-Onset Asthma, and Others. Severe eosinophilic asthma is the largest segment in the asthma biologics market. This form of asthma has attracted a lot of attention as a result of the increasing presence of eosinophilic inflammation in patients with severe asthma. Monoclonal antibodies (e.g., benralizumab, mepolizumab) that target eosinophilic pathways have demonstrated a significant level of efficacy in both exacerbation reduction and overall asthma management. This segment is growing fast, fueling innovations and biologics market expansion as more research and clinical evidence are emerging to support their efficacy. It also has some great prospects for pharmaceutical companies specializing in precision medicine for asthma.

Based on the Drug Class, the Asthma Biologics Market has been classified into Anti-IgE, Anti-IL5, Anti-IL4/IL13, Anti-TSLP, and Others. Anti-IL5 is the most important drug class in the asthma biologics market. The interleukin-5 (IL-5) targeting has demonstrated a great effect on patients with severe eosinophilic asthma, which is the prevailing type of asthma biologics. IL-5 is also vital in the activation and maintenance of eosinophils, which are at the heart of the asthma inflammatory response. Anti-IL5 therapies are the most effective on the market, with biologics like mepolizumab, reslizumab, and benralizumab proving to be very effective in reducing exacerbations and improving lung function. The increase in the use of such therapies shows their effectiveness in controlling serious symptoms of asthma.

Which regions are leading the Asthma Biologics market, and why?

The North American asthma biologic market is leading owing to a number of factors. The region enjoys strong healthcare facilities, high investments in research and development, and the acquisition of major pharmaceuticals. There has been an increased prevalence of asthma, especially in the U.S., leading to the need to develop new biologic therapies that are more effective and precise treatments as opposed to conventional inhalers. Further, effective regulatory encouragement by agencies such as the FDA and awareness and access to healthcare have enabled market expansions.

The preferential trend of biologics, especially monoclonal antibodies, and the move towards personalized medicine also make North America a leader in this market. Moreover, the presence of many clinical trials and alliances of biotech companies is also an influential factor in the direction of development in the region.

The Asia-Pacific region asthma biologics market is expanding as a result of a number of reasons. As the prevalence of asthma in countries such as China, India, and Japan is on the rise, there is great concern regarding the need to come up with sophisticated biologic therapies to cope with the condition. The rise in awareness of asthma management therapeutic options and the advancement in the health care infrastructure have led to the adoption of biologics. The region is also characterized by an increase in the middle class that has improved access to novel therapies.

Strategic partnerships between pharmaceutical firms and local authorities have also helped in the arrival and spread of biologic medications in the region. The market is further on its path of expansion due to the level of investment in research and development, turning to make Asia-Pacific a prime location in terms of asthma biologics. The fact of increasing healthcare spending and positive regulatory conditions in the region has been keeping the international players, who, in turn, fuel the competition and innovativeness. Consequently, there will be faster growth of the market in the next few years.

What does the competitive landscape of the Asthma Biologics market look like?

The asthma biologics market is very competitive, and such important players as Amgen, AstraZeneca, Novartis, and Sanofi take the lead in the creation and commercialisation of new therapies. More recent development concerns AstraZeneca, which has strongly concentrated on biologics, such as Dupixent (in partnership with Sanofi), which demonstrated good outcomes in the treatment of severe asthma. Amgen has also forged ahead with its pipeline in asthma biologics as it makes the most of its experience in monoclonal antibodies. Novartis and Regeneron are establishing themselves with next-gen biologics that target particular cytokines that play a role in asthma pathogenesis.

In the market, there has been greater co-operation, such as between GSK and Innoviva, in improving inhaled biologic solutions. As regulatory approvals and partnerships continue to rise, companies are aggressively searching for how to expand indications, extend patent protection, and create market penetration in the international market, and more so in emerging markets. The environment is evolving because large pharmaceutical companies and biotech startups are investigating new biologic pathways to meet unmet clinical demands in the management of asthma.

Asthma Biologics Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Asthma Biologics industry?

• In March 2025, Connect Biopharma published positive Phase 2 data for rademikibart, an anti-IL-4Rα monoclonal antibody. In moderate-to-severe, Type 2-driven asthma patients, it showed significant improvements in FEV₁ and reduced exacerbations without causing hypereosinophilia. The FDA approved the progression to Phase 3 after an End-of-Phase 2 meeting.
• In May 2024, GSK announced that depemokimab, its experimental biologic for eosinophilic asthma, met primary endpoints in a Phase 3 trial, significantly reducing asthma attacks. GSK anticipates peak sales of up to £3 billion for this ultra-long-acting biologic, which may have a six-month dosing interval.

Report Coverage:

By Asthma Type

• Severe Eosinophilic Asthma
• Allergic Asthma
• Non-Eosinophilic Asthma
• Late-Onset Asthma
• Others

By Drug Class

• Anti-IgE
• Anti-IL5
• Anti-IL4/IL13
• Anti-TSLP
• Others

By Age Group

• Pediatric Patients
• Adults
• Geriatric Patients

By Route of Administration

• Subcutaneous (SC)
• Intravenous (IV)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Specialty Clinics
• Online Pharmacies

By End User

• Hospitals
• Specialty Clinics & Pulmonology Centers
• Research & Academic Institutes
• Homecare Settings

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Amgen Inc.
• AstraZeneca
• Novartis International AG
• GlaxoSmithKline (GSK)
• Regeneron Pharmaceuticals
• Sanofi
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Merck & Co., Inc.
• Eli Lilly and Company
• Boehringer Ingelheim GmbH
• Roche
• Johnson & Johnson
• Pfizer Inc.
• UCB Pharma

Frequently Asked Questions (FAQs)